Gene expression profile of mitogen-activated kinases and microRNAs controlling their expression in HaCaT cell culture treated with lipopolysaccharide A and cyclosporine A

Cell Cycle. 2024 Feb;23(3):279-293. doi: 10.1080/15384101.2024.2320508. Epub 2024 Mar 6.

Abstract

Studies indicate that mitogen-activated protein kinases (MAPKs) are activated and overexpressed in psoriatic lesions. The aim of the study was to assess changes in the expression pattern of genes encoding MAPKs and microRNA (miRNA) molecules potentially regulating their expression in human adult low-calcium high-temperature (HaCaT) keratinocytes exposed to bacterial lipopolysaccharide A (LPS) and cyclosporine A (CsA). HaCaT cells were treated with 1 µg/mL LPS for 8 h, followed by treatment with 100 ng/mL cyclosporine A for 2, 8, or 24 h. Untreated cells served as controls. The molecular analysis consists of microarray, quantitative real-time polymerase chain reaction, and enzyme-linked immunosorbent assay analyses. The statistical analysis of the obtained results was performed using Transcriptome Analysis Console and STATISTICA 13.5 PL with the statistical significance threshold of p < 0.05. Changes in the expression profile of six mRNAs: dual-specificity phosphatase 1 (DUSP1), dual-specificity phosphatase 4 (DUSP4), mitogen-activated protein kinase kinase 2 (MAP2K2), mitogen-activated protein kinase kinase 7 (MAP2K7), mitogen-activated protein kinase kinase kinase 2 (MAP3K2) and mitogen-activated protein kinase 9 (MAPK9) in cell culture exposed to LPS or LPS and the drug compared to the control. We observed that under the LPS and cyclosporine treatment, the expression o/ miR-34a, miR-1275, miR-3188, and miR-382 changed significantly (p < 0.05). We demonstrated a potential relationship between DUSP1 and miR-34a; DUSP4 and miR-34a, miR-382, and miR-3188; MAPK9 and miR-1275, MAP2K7 and mir-200-5p; MAP3K2 and mir-200-5p, which may be the subject of further research in the context of psoriasis.

Keywords: Mitogen-activated protein kinases; bacterial lipopolysaccharide A; cyclosporine A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Cyclosporine* / pharmacology
  • Dual Specificity Phosphatase 1 / genetics
  • Dual Specificity Phosphatase 1 / metabolism
  • Dual-Specificity Phosphatases / genetics
  • Dual-Specificity Phosphatases / metabolism
  • Gene Expression Profiling
  • Gene Expression Regulation / drug effects
  • HaCaT Cells
  • Humans
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Lipopolysaccharides* / pharmacology
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Mitogen-Activated Protein Kinase Phosphatases / genetics
  • Mitogen-Activated Protein Kinase Phosphatases / metabolism
  • Mitogen-Activated Protein Kinases* / genetics
  • Mitogen-Activated Protein Kinases* / metabolism
  • Psoriasis / drug therapy
  • Psoriasis / genetics
  • Transcriptome / drug effects
  • Transcriptome / genetics

Substances

  • Cyclosporine
  • MicroRNAs
  • Lipopolysaccharides
  • Mitogen-Activated Protein Kinases
  • Dual-Specificity Phosphatases
  • Dual Specificity Phosphatase 1
  • Mitogen-Activated Protein Kinase Phosphatases
  • DUSP1 protein, human
  • DUSP4 protein, human

Grants and funding

This research received no external funding.